Bronte Capital

The sometimes eccentric views of John Hempton

Tuesday, January 3, 2017

Valuation and investment analysis

›
I just had a chat with someone who wondered why I did not have a valuation for everything in my portfolio - a buy and a sell price. My rea...
49 comments:
Wednesday, December 28, 2016

Did Mike Tyson ring a bell?

›
They say nobody rings a bell at the top. But this is pretty good... It's Mike Tyson promoting online trading platform Trade12. Wh...
3 comments:
Friday, December 16, 2016

UCB: Lower standards in Belgium

›
The last two posts on this blog detail how - for all practical purposes - UCB (the large Belgian pharmaceutical company) has lost the paten...
7 comments:
Monday, December 12, 2016

UCB's lack of candour

›
This is a follow up to last Friday's post about UCB - the large Belgian pharmaceuticals company. It probably helps if you read  that po...
1 comment:
Friday, December 9, 2016

UCB's Vimpat patent

›
UCB  is a Belgium-based biopharmaceutical and specialty chemical company that specialises in two therapeutic areas: diseases of the central ...
2 comments:
Thursday, December 8, 2016

In praise of Donald Trump's conflicts of interest

›
There is an obsession in the liberal press about Donald Trump's opaque personal finances and the repeated appearance that he has a confl...
14 comments:
‹
›
Home
View web version

About me

View my complete profile
Powered by Blogger.